GlassScriptPhysician profile
Stephen John Vara
NPI 1356545818
$4,091.55
in general payments reported to CMS, 2019-2025
44 companies · $1,094 in 2025
The $1,094 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.66 · 2021: $203 · 2022: $1,283 · 2023: $703 · 2024: $756 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $434.75 | 2022-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $432.20 | 2022-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $332.00 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $266.67 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $254.24 | 2022-2025 | |
| Celgene Corporation | $236.70 | 2022-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $233.36 | 2022-2024 | |
| Gilead Sciences, INC. | $217.94 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $200.15 | 2019-2024 | Tecentriq, Alecensa, Polivy |
| Abbvie INC. | $170.57 | 2021-2025 | |
| Seagen INC. | $165.36 | 2019-2023 | Tukysa |
| Array Biopharma INC | $130.75 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Exelixis INC. | $129.50 | 2021-2025 | Cabometyx |
| Springworks Therapeutics, INC. | $58.77 | 2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $56.54 | 2022-2025 | Besremi |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.